Agency Commissioner Marti Makeri told CNBC on Friday that the drug and drug administrative companies would consider drug ability while providing new vouchers.
FDA announced in June National priority voucher scheme Its purpose is to cut the drug review time for companies for one-two months to say that “American national interests” are supporting. But previous Announcements In the voucher program, it was clearly not mentioned to make drugs more inexpensive as a criterion.
“We are incorporating the strength of drugs as a national priority,” Makri told CNBC.
Reducing drug prices is a major goal of Trump administration, facing a difficult balance act because it is a threat 200% tariff on pharmaceuticals The US was imported into a bid to resume drug manufacturing.
Food and Drugs Administration Marti Mary spoke at a news conference at a news conference at a news conference at a news conference on the removal of synthetic pigments from the health of the US at Washington, DC on 22 April 2025, DC.
Nathan Posner | Anadolu | Getty images
Makri said that President Donald Trump “is very adamant that he will reduce drug prices for Americans, and does not like that Americans are bursting with two, five, 10 times more” drugs in the US than other developed countries.
But it is not clear how the Trump administration will consider the ability when reviewing a drug, as prices for the launch of a product are usually determined after approval in the US.
FDA Website Currently underlines four examples of “national priorities” which will be used to determine which companies will get vouchers under the new program. It includes addressing a health crisis in the US, providing “more innovative treatment” to Americans, addressing public health requirements, and “increasing domestic medicine as a national security issue”.
According to Wall Street Journal, drug ability can be included first Report In June.
A spokesperson of the Department of Health and Human Services confirmed that the FDA would consider drug ability to the program, not limited to examples before adding criteria.
It has been said to provide an example of a health crisis that companies can meet with their drugs, Makeri said that she wants to see a cure for type 1 diabetes, more treatment for neurodygenettive diseases and a universal flu shot “So we don’t have to guess which stress is coming.”
He also said that he wants to see more treatment for stage 4 cancer, or when the disease has spread from its original site to distant parts of the body.
“We have a committee established that will determine which products and companies will get these vouchers as part of a pilot,” Makri said. “But we have got to try new things. We have to ask ourselves, why it takes so much time to come to the market? And we want to see more treatment and meaningful treatment for Americans.”
FDA will give new vouchers this year. After a one -year pilot phase, agency may increase the number of quick approval given to companies.
Some Wall Street analysts have earlier stated that the voucher program may be more effective than tariffs to encourage drug manufacturing to bring their manufacturing to the US.
But the risks of intensifying the drug review are less up to 30 days, the fastest ever by the FDA.
Another possible concern is whether the FDA will provide vouchers to the political colleagues of the Trump administration, which may include companies that agency employees will normally examine.
